The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.

The genomic diagnostics product developer secured $16.2m in a round led by Heda's healthcare investment arm, adding to a $9m series A in 2017.

The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.

SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.

The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.

Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.